PLoS ONE · 2014 · 19 citations · 19 references
The prognosis of advanced HCC patients with EHM is significantly worse than those without EHM administered repeated TACE treatments, even if their tumor stage was similar to BCLC stage C. These results suggest that EHM presence means aggressive tumor biology and that BCLC stage C might be subclassified according to EHM presence.
19
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 12.8K citations · Full text
Management of Hepatocellular Carcinoma: An Update Δσ
Jordi Bruix, Morris Sherman · Hepatology · 2011 · 8.1K citations · Full text
Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations
Sorafenib in Advanced Hepatocellular Carcinoma
재연 정 · 2008 · 5.6K citations
Hepatology, Medicine, Pathology +5